ArticleScientific reports2025
Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In recent years, antibody-drug conjugates have become clinically significant in oncology therapeutics. Results from the POLARIX trial revealed that polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported a 7.7% improvement in the 3-year progression-free survival (PFS), with no difference in overall survival (OS). This study aimed to assess the cost-effectiveness of polatuzumab vedotin in the first-line treatment of diffuse large B-cell lymphoma (DLBCL) from the perspective of the Chinese healthcare system. We constructed a 3-state partitioned survival model and a 10-year horizon to estimate the cost and utility associated with DLBCL treatment. The survival data, direct medical costs, and utilities were obtained from the POLARIX trial, YAOZHI database, and published literature. The outputs of the model include total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Uncertainty was explored through one-way, probabilistic sensitivity and scenario analyses. Over a 10-year horizon, Pola-R-CHP provided an additional 0.29 QALYs versus R-CHOP, while incurring incremental costs of $31,804 and an ICER of $110,594/QALY. One-way sensitivity analysis suggested that the model was most sensitive to the utility of PFS and the cost of polatuzumab vedotin. Probabilistic sensitivity analysis showed that at the willingness-to-pay (WTP) threshold ($38,043), Pola-R-CHP was not considered cost-effective. Scenario analyses indicated that Pola-R-CHP could be a cost-effective therapeutic alternative for patients achieving long-term survival. The threshold analysis demonstrated that a 61% price reduction for polatuzumab vedotin would achieve cost-effectiveness at the WTP threshold. In the first-line treatment of DLBCL, Pola-R-CHP provides an additional health benefit over R-CHOP, but is unlikely to be cost-effective at currently published prices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.